The Brazilian stock exchange Ibovespa is set for a stellar opening today, as Ibovespa futures jumped 3.6 percent after news that Pfizer and BioNTech’s potential Covid-19 vaccine BNT162b2 showed 90-percent efficiency in tested patients.
The Brazilian Real has gained over 2 percent against the U.S. Dollar, with the American currency being traded in the country at BRL 5.26. Negative variations were also seen in the bonds market.
An independent report on late-stage Pfizer vaccine trials showed an efficacy rate of above 90 percent seven days after a second dose. This would suggest protection against the virus is achieved four weeks after the first vaccination.
The drugmakers will now submit the vaccine for Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration, hoping for approval in the third week of November.
Pfizer and BioNTech said that no serious safety concerns have been observed among the studies’ 43,538 participants, but additional efficacy and safety data are still being collated. As we reported earlier in July, 5,000 candidates in the Brazilian states of Bahia and São Paulo took part in the BNT162b2 trials.
Based on projections, the companies expect to supply up to 50 million doses globally in 2020, and manufacture up to 1.3 billion doses in 2021.
Support this coverage →The city of Rio de Janeiro estimates that a Madonna concert this Saturday on Copacabana…
Latin America’s trend of banning opposition candidates from elections has caught on in an ever-growing…
The São Paulo City Council on Thursday approved legislation authorizing Brazil’s largest city to sign…
The preliminary report on AI regulations presented to Brazil’s Senate last week provides a middle-of-the-road…
In 2000, Formula 1 great Michael Schumacher had just racked up his 41st race win,…
Overall, the worldwide economic outlook has improved according to the Organization for Economic Co-operation and…